STOCK TITAN

Insider Notice: Sionna Proposes Sale of 34,500 Shares on 08/19/2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Sionna Therapeutics (SION) filing of a Form 144 notifies the proposed sale of 34,500 shares of common stock through Morgan Stanley Smith Barney LLC on 08/19/2025. The shares have an aggregate market value of $737,955.00 and the company reports 44,139,823 shares outstanding. The securities were acquired on 09/20/2022 through previously exercised stock options from the issuer and were paid for in cash. The filer reports "Nothing to Report" for securities sold during the past three months. The notice includes the filers representation that they do not possess undisclosed material adverse information.

Positive

  • Regulatory compliance: The filer provided required Rule 144 disclosure details, including broker, share count, and acquisition history.
  • Transparency: Acquisition date (09/20/2022) and payment method (cash) are disclosed, aiding market clarity.

Negative

  • Insider sale planned: The proposed sale of 34,500 shares by an insider may be perceived negatively by some investors.

Insights

TL;DR: Routine insider notice of proposed sale; transparent reporting but not materially transformative.

The Form 144 documents a planned sale of 34,500 common shares via Morgan Stanley Smith Barney LLC with an aggregate market value of $737,955. The shares were acquired by previously exercised options on 09/20/2022 and paid in cash. The filing states no sales in the past three months. This is a standard regulatory disclosure that enables market transparency about an insider-affiliated sale. The filing itself contains no earnings, financing, or covenant changes and does not disclose any undisclosed adverse information per the signers representation.

TL;DR: Proper compliance with Rule 144 reporting requirements; procedural rather than material news.

The notice provides required details: broker name and address, number of shares, acquisition date and method (previously exercised stock options), and payment nature (cash). It confirms no related sales in the prior three months and includes the standard signature representation about material information. From a governance perspective, the filing demonstrates adherence to disclosure rules but does not, by itself, indicate governance changes or material corporate events.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for SION disclose?

The Form 144 discloses a proposed sale of 34,500 common shares through Morgan Stanley Smith Barney LLC on 08/19/2025 with an aggregate market value of $737,955.00.

How and when were the shares being sold acquired?

The shares were acquired on 09/20/2022 via previously exercised stock options from the issuer and were paid for in cash.

Does the filing report recent sales by the same person?

The filing states "Nothing to Report" for securities sold during the past three months.

How many shares outstanding does Sionna report in this notice?

The notice lists 44,139,823 shares outstanding.

Which broker is handling the proposed sale?

The broker named in the filing is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York NY 10004.
Sionna Therapeutics

NASDAQ:SION

SION Rankings

SION Latest News

SION Latest SEC Filings

SION Stock Data

1.67B
30.22M
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM